Evidence map›Paper›PMID 40270210›Full record

ArticleHLA2025

Cost-Effective and Highly Scalable Typing of HLA Classes I and II Genes of up to 96 Individuals Using Nanopore Sequencing.

Frederikke Byron Pedersen, Anne Werner Hauge, Jacob Flemming Hansen, Laura Studnitz Andersen, Signe Blomsterberg, Helle Bruunsgaard

Abstract read
In one paragraph

Article in HLA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Frederikke Byron PedersenDepartment of Clinical Immunology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-4433-7268
Anne Werner HaugeDepartment of Clinical Immunology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-4731-1768
Jacob Flemming HansenUniversity College Copenhagen, Copenhagen, Denmark.ORCID 0009-0008-2754-2551
Laura Studnitz AndersenUniversity College Copenhagen, Copenhagen, Denmark.ORCID 0009-0003-4020-2686
Signe BlomsterbergUniversity College Copenhagen, Copenhagen, Denmark.ORCID 0009-0005-6525-0646
Helle BruunsgaardDepartment of Clinical Immunology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-2330-0834

Funding

Bloddonorernes Forskningsfond FF 2022/01
6 · The paper itself

Abstract

HLA typing of large donor registries and biobanks as well as acute single patient/donor samples remains expensive, slow and logistically challenging, despite recent developments in the field. We have tested and validated a cost-effective, accurate and highly scalable method for typing specific genes in the HLA region. This enables HLA typing from 1 to 96 individuals simultaneously, using a targeted PCR and Native Barcoding kit from Oxford Nanopore Technologies. A primer set for seven HLA genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 and -DPB1) was developed to work in a multiplex PCR reaction. The resulting amplicons provide a possible four-field resolution of the HLA Class I genes and G-group resolution of the HLA Class II genes. The entire process, from DNA to HLA typing result, takes a total of 5.5-10.5 h depending on the number of samples processed simultaneously. Data analysis was conducted using NGSEngine-Turbo from GenDx (Utrecht, The Netherlands), with analysis time ranging from 1 to 5 min per sample. Samples from 96 Danish registered stem cell donors were typed using this method. One allele out of 1128 analysed alleles was inaccurately called homozygous, leading to an accuracy of 99.91%. The rapid turnaround, low cost and high accuracy make this new method highly relevant for HLA typing of large biobanks and donor registries, as well as for acute single samples. HLA typing can be obtained within 1 day, with a cost per sample of approximately €7 when 96 samples are sequenced simultaneously.

Indexed as

Histocompatibility Antigens Class IIHistocompatibility TestingNanopore SequencingAllelesCost-Benefit AnalysisHumansMultiplex Polymerase Chain ReactionHistocompatibility Antigens Class IIcost‐effectivehigh‐throughputHLAlong‐read sequencingnanoporenative barcoding

Identifiers

PMID40270210
PMCPMC12019580

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.